Bitterfeld-Wolfen (Germany), 30 August 2012 - Today, Henning Schorisch, lawyer and insolvency administrator for the assets of Q-Cells SE (ISIN DE0005558662), applied with the management of the Frankfurt Stock Exchange for the revocation of Q-Cells SE’s admission to the regulated market (General Standard) regarding its shares pursuant to section 39 (2) Stock Exchange Act (Börsengesetz) in conjunction with section 46 (1) Stock Exchange Order (Börsenordnung).
The shares of Q-Cells SE are currently listed on the Frankfurt Stock Exchange in the regulated market sub-section with additional obligations arising from admission (Prime Standard). The revocation of this admission has already been applied for and approved by the management of the Frankfurt Stock Exchange. Admission to the regulated market sub-section with additional obligations arising from admission (Prime Standard) of the Frankfurt Stock Exchange will terminate at midnight on 18 October 2012. As a direct result, the Q-Cells SE shares will be admitted for trading on the regulated market (General Standard) of Frankfurt Stock Exchange (a legally required step) on 19 October 2012.
Today’s application for the revocation of admission to the regulated market (General Standard) aims to terminate this (last remaining) admission of the shares to a regulated market so that the Q-Cells SE shares will be fully delisted as soon as today’s application becomes effective.
Q-Cells SE i.I.
OT Thalheim, Sonnenallee 17-21
06766 Bitterfeld-Wolfen, Germany
FAX +49 (0)3494 6699.10000
Q.CELLS Investor Relations
TEL +49 (0)3494 6699.10101
Q.CELLS Corporate Communications
Ina von Spies, Alberta Rohardt
TEL +49 (0)3494 6699.10121
Lawyer Henning Schorisch as insolvency administrator of Q-Cells SE
Executive Board: Dr Nedim Cen (CEO, CFO), Dr Andreas v. Zitzewitz (COO, CSO)
Chairman of the Supervisory Board: Prof Dr h c Karlheinz Hornung